Cancer name Skin Cutaneous Melanoma
Cancer Type SKCM
Immunotherapy type Cancer Vaccine
Treatment p19(Arf)
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature IFN-γ
Official Symbol IFNG
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Bead array analysis revealed in both the IFN-β and the combination groups an increase in cytokines associated with a TH1 immune response (IL-12, IL-6, TNF-α, IFN-γ, MCP1/CCL2), and with the exception of IL-10, no alteration was seen in the TH2 and TH17 profile.
PMID 26887933
Title Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy.